IDO1 inhibitor, Ipilimumab clinical trials

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

This study looks at new ways to treat advanced cancers using a combination of different medications. Researchers want to see how safe these combinations are and how well they work to shrink tumours or stop them from growing.